Institutional Scholarship

Understanding the Hatch-Waxman Act Through Effective Patent Length

Show simple item record

dc.contributor.advisor Ball, Richard J. Vucovich, Nathan 2021-07-12T12:44:11Z 2021-07-12T12:44:11Z 2021
dc.description.abstract The Hatch-Waxman Act was made law September 24, 1984. The goal of this law was to decrease the barriers to enter into the market for generic drugs while maintaining incentives for researching new drugs. The Act decreased the time it took to approve ageneric through the ANDA and allowed generic companies the right to research using the original drug while it was still patented. In return the originally marketed drug received the right to recoup some of the time lost on its patent from the FDA approval process. To measure if this it true, I looked at the effective patent length of original drugs before and after Hatch-Waxman. The effective patent length is the time the original drug has no market competition. In order to maintain incentives to research, this length needs to stay the same or increase. This is due to low switching costs from original to generic drugs. To show that the Act decreased barriers to entry into the market, I looked at new generic market entries for specific compounds before and after Hatch-Waxman. Overall, the Hatch-Waxman Act was ineffective at maintaining incentives for research and development by keeping the effective patent length the same (or market exclusivity), but was successful in increasing generic competition.
dc.description.sponsorship Haverford College. Department of Economics
dc.language.iso eng
dc.subject.lcsh Drugs -- Generic substitution -- Law and legislation -- United States
dc.subject.lcsh Drugs -- United States -- Patents
dc.title Understanding the Hatch-Waxman Act Through Effective Patent Length
dc.type Thesis
dc.rights.access Open Access

Files in this item

This item appears in the following Collection(s)

Show simple item record Except where otherwise noted, this item's license is described as



My Account